@entity1311 / @entity136 administered every two weeks in XXXX : preliminary results of a phase II trial.

@entity1 @entity137 @entity390 @entity0 @entity882 @entity391 @entity1311 @entity1398 @entity492 @entity1142 @entity136
The purpose of this study was to evaluate the @entity137 and efficacy of @entity1311 / @entity136 administered every 2 weeks in the first-line treatment of @entity0 . Forty-three chemonaive @entity1 with histologically confirmed metastatic @entity0 were enrolled. @entity1 received @entity1311 150 mg/m2 followed by @entity136 2,500 mg/m2, both on day I of a 14-day cycle, for a maximum of eight cycles. Thirty-four @entity1 were evaluable for @entity137 ; 38 were evaluable for efficacy. The median age at the time of diagnosis was 54 years, the median performance status was 90, and the median number of lesions was three. Most @entity1 (71%) had received prior adjuvant therapy. Grade 3 and 4 @entity137 was limited to leukocytes (14% and 18%, respectively). Grade 3 @entity137 (5% each) were @entity882 , @entity390 and @entity391 , elevation of @entity492 transaminase, neurosensory, and @entity1142 . One @entity1 had @entity1398 and fever. The objective response rate was 68% (21% complete response and 47% partial response); 18% had stable disease and 13% had partial disease. The preliminary evaluation of @entity1311 / @entity136 given as a 2-week schedule to @entity1 with untreated advanced @entity0 shows encouraging activity and a favorable @entity137 profile.
